Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2025 | Selecting patients with breast cancer for neratinib after neoadjuvant HER2 therapy

Rupert Bartsch • 23 Dec 2025
SABCS 2025
Breast Cancer Neratinib Trastuzumab emtansine

Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, highlights the potential candidates with breast cancer for neratinib treatment. The integration of trastuzumab emtansine (T-DM1) in the neoadjuvant setting may impact the use of neratinib, particularly in patients with hormone receptor-positive, HER2-positive disease, and neratinib may still be beneficial in patients with residual tumor load after T-DM1 treatment. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rupert Bartsch

Clinical challenges in managing CNS metastases in HER2+ breast cancer
3:04
Clinical challenges in managing CNS metastases in HER2+ breast cancer
Rupert Bartsch • 23 Dec 2025
Real-world safety of extended adjuvant neratinib: interim NERLYFE data
2:30
Real-world safety of extended adjuvant neratinib: interim NERLYFE data
Rupert Bartsch • 23 Dec 2025
TUXEDO-3: HER3-DXd after T-DXd in HER2+ breast cancer with CNS involvement
3:00
TUXEDO-3: HER3-DXd after T-DXd in HER2+ breast cancer with CNS involvement
Rupert Bartsch • 23 Dec 2025
Post-ADC treatment strategies in HER2+ breast cancer
10:57
Post-ADC treatment strategies in HER2+ breast cancer
Rupert Bartsch • 20 May 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals